Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Dalteparin Sodium

Dalteparin Sodium: An In-Depth Overview

Introduction

Dalteparin sodium is an anticoagulant, commonly known as a low-molecular-weight heparin (LMWH), used primarily to prevent and treat blood clots in the veins and arteries. This medication plays an essential role in managing conditions like deep vein thrombosis (DVT), pulmonary embolism (PE), and in preventing clot formation in patients undergoing certain types of surgery, such as hip or knee replacement. Dalteparin, like other LMWHs, offers significant advantages over traditional unfractionated heparin (UFH), including a more predictable anticoagulant effect and a lower risk of bleeding complications.

Dalteparin Sodium

Dalteparin sodium is a synthetic, low-molecular-weight version of heparin, a naturally occurring anticoagulant. Heparin has long been used in the medical field to treat and prevent clotting disorders. Dalteparin, along with other LMWHs like enoxaparin and tinzaparin, was developed to offer a more convenient and predictable anticoagulation profile compared to unfractionated heparin. Low-molecular-weight heparins like dalteparin are derived from standard heparin by depolymerizing it into smaller fragments. These smaller fragments retain the anticoagulant properties of heparin but are easier to manage due to their more predictable pharmacokinetics and a lower incidence of side effects.

Mechanism of Action

Dalteparin sodium exerts its anticoagulant effects by enhancing the activity of antithrombin III, a natural inhibitor of clotting factors in the blood. Specifically, dalteparin primarily inhibits the activity of two key clotting factors: factor Xa and thrombin (factor IIa).

  1. Inhibition of Factor Xa: Dalteparin binds to antithrombin III, causing a conformational change that increases its ability to inhibit factor Xa. Factor Xa is crucial in the conversion of prothrombin to thrombin, and by inhibiting it, dalteparin reduces thrombin formation, which is a critical step in clotting.

  2. Inhibition of Thrombin (Factor IIa): Dalteparin also inhibits thrombin (factor IIa) in a dose-dependent manner, although its primary effect is on factor Xa. By inhibiting thrombin, dalteparin reduces the ability of platelets to aggregate and promotes the breakdown of fibrin, preventing clot formation.

The primary advantage of dalteparin over unfractionated heparin is that it predominantly inhibits factor Xa and has a less significant effect on thrombin. This results in a more predictable anticoagulant effect, with fewer requirements for monitoring and dose adjustments.

Clinical Uses of Dalteparin Sodium

Dalteparin is widely used in clinical practice to treat or prevent thromboembolic events. The primary indications for dalteparin include:

1. Prevention of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

One of the most common uses of dalteparin is for the prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly in patients undergoing major surgery or those who are at high risk of developing these conditions. Surgery involving the hips, knees, or abdominal regions is particularly associated with an increased risk of DVT due to reduced mobility and changes in blood flow. Dalteparin is also used in medical patients who are bedridden due to illness, as immobility is a known risk factor for clot formation. By inhibiting clotting factors, dalteparin helps to reduce the likelihood of DVT and subsequent pulmonary embolism.

2. Treatment of Existing DVT and PE

Dalteparin is also used for the treatment of established deep vein thrombosis (DVT) and pulmonary embolism (PE). For patients with diagnosed DVT or PE, dalteparin is often given as part of an acute treatment regimen to prevent the clot from enlarging and to reduce the risk of further clot formation. In such cases, dalteparin is typically used in combination with other anticoagulants such as warfarin or direct oral anticoagulants (DOACs).

3. Acute Coronary Syndrome (ACS)

In patients with acute coronary syndrome (ACS), including unstable angina and non-ST elevation myocardial infarction (NSTEMI), dalteparin is used to prevent the formation of blood clots in the coronary arteries. The use of dalteparin helps reduce the risk of further complications like heart attacks or strokes by inhibiting clot formation in the coronary circulation.

4. Prevention of Clot Formation During Dialysis

Dalteparin is also used in patients undergoing dialysis. During dialysis, patients' blood is passed through a machine, which increases the risk of clot formation in the dialysis circuit. Dalteparin is used to prevent such clots, ensuring that the dialysis process is effective and uninterrupted.

5. Prevention of Clots in Cancer Patients

Patients with cancer are at an elevated risk of developing thromboembolic events due to both the cancer itself and its treatments, such as chemotherapy. Dalteparin has been shown to reduce the incidence of venous thromboembolism in cancer patients, and it is sometimes used in this population to prevent DVT and PE.

Dosing and Administration

Dalteparin is administered by subcutaneous injection. The dosing regimen depends on the condition being treated and the patient's individual risk factors.

1. Dosing for DVT/PE Prevention

For the prevention of DVT in patients undergoing surgery or those at risk of venous thromboembolism, the typical dose is:

  • Adults (general prevention): 2,500 to 5,000 units once daily, administered subcutaneously.

2. Dosing for Treatment of DVT/PE

For patients with established deep vein thrombosis or pulmonary embolism, dalteparin is usually dosed as follows:

  • Initial dose: 200 units/kg of body weight once daily, administered subcutaneously for the first 5 to 7 days.

  • Maintenance dose: After the initial loading dose, the maintenance dose is typically 150 units/kg of body weight, administered once daily.

3. Acute Coronary Syndrome (ACS)

In ACS patients, dalteparin is used in combination with other treatments, and the typical dosing is:

  • Initial dose: 120 units/kg subcutaneously every 12 hours, depending on the severity of the condition.

4. Dialysis

For dialysis, dalteparin is used as a heparin-like anticoagulant to prevent clotting during the procedure. The dosage is typically based on the patient’s weight and individual needs, but the starting dose is generally 5,000 to 10,000 units.

Side Effects of Dalteparin Sodium

Like all medications, dalteparin sodium has the potential for side effects. Most side effects are mild and related to its anticoagulant action. However, serious adverse events can occur, especially if dalteparin is not used according to medical guidance.

Common Side Effects:

  1. Bleeding: The most significant side effect of dalteparin is bleeding. This can range from minor bruising to more severe bleeding events, such as gastrointestinal or intracranial bleeding. Regular monitoring and dose adjustments are essential to minimize this risk.

  2. Injection Site Reactions: Patients may experience redness, swelling, or pain at the injection site. These reactions are usually mild and resolve on their own.

  3. Anemia: Dalteparin can occasionally cause a reduction in red blood cell count, leading to anemia. Symptoms of anemia may include fatigue, weakness, and shortness of breath.

  4. Thrombocytopenia: A decrease in platelet count can occur in some patients, though this is less common with LMWHs like dalteparin compared to unfractionated heparin. Severe thrombocytopenia can increase the risk of bleeding.

  5. Elevated Liver Enzymes: In rare cases, dalteparin can cause mild elevations in liver enzymes. These changes are usually transient and resolve after discontinuation of the drug.

Serious Side Effects:

  1. Major Bleeding Events: Serious bleeding, including intracranial hemorrhage or gastrointestinal bleeding, although rare, can occur. Immediate medical attention is required if patients experience signs of major bleeding, such as prolonged nosebleeds, blood in the stool, or coughing up blood.

  2. Heparin-Induced Thrombocytopenia (HIT): Although HIT is more commonly associated with unfractionated heparin, there is still a risk with dalteparin, particularly in patients who have been treated with heparin previously. HIT is characterized by a severe drop in platelet count and paradoxical thrombotic events.

Drug Interactions

Dalteparin sodium can interact with other medications, which may increase the risk of bleeding or reduce the efficacy of the treatment. Some key drug interactions include:

  1. Antiplatelet Agents: When combined with other anticoagulants or antiplatelet medications, such as aspirin or clopidogrel, the risk of bleeding increases.

  2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): NSAIDs, such as ibuprofen, can exacerbate bleeding risk when used with dalteparin.

  3. Anticoagulants: Combining dalteparin with other anticoagulants (like warfarin or other LMWHs) can lead to an increased risk of bleeding and should generally be avoided unless monitored closely.

  4. Rifampin: Rifampin, a potent inducer of liver enzymes, may reduce the effectiveness of dalteparin by accelerating its metabolism.

Conclusion

Dalteparin sodium is a valuable medication in the prevention and treatment of thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), and acute coronary syndrome (ACS). As a low-molecular-weight heparin (LMWH), dalteparin offers many advantages over unfractionated heparin, including more predictable anticoagulant effects, easier administration, and a lower risk of side effects like heparin-induced thrombocytopenia (HIT). Although dalteparin is generally well-tolerated, its primary side effect, bleeding, requires careful monitoring, especially when used in combination with other anticoagulants or in patients with certain medical conditions. As with all anticoagulants, the risks must be carefully balanced against the therapeutic benefits, and dalteparin should only be used under the supervision of a healthcare professional.